ClinicalTrials.gov record
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov ID: NCT00400153
Public ClinicalTrials.gov record NCT00400153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.
Study identification
- NCT ID
- NCT00400153
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,480 participants
Conditions and interventions
Conditions
Interventions
- Atrovent Respimat (20 mcg) Drug
- COMBIVENT MDI (36/206 mcg) Drug
- Combivent Respimat (20 mcg/100 mcg) Drug
- Placebo via corresponding inhaler for blinding purposes Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Mar 31, 2008
- Completion
- Not listed
- Last update posted
- Jun 12, 2014
Started 2006
United States locations
- U.S. sites
- 87
- U.S. states
- 31
- U.S. cities
- 77
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1012.56.01006 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1012.56.01051 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1012.56.01071 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1012.56.01039 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1012.56.01012 Boehringer Ingelheim Investigational Site | Lakewood | California | — | — |
| 1012.56.01029 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1012.56.01043 Boehringer Ingelheim Investigational Site | Palo Alto | California | — | — |
| 1012.56.01089 Boehringer Ingelheim Investigational Site | Rancho Mirage | California | — | — |
| 1012.56.01021 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1012.56.01033 Boehringer Ingelheim Investigational Site | San Jose | California | — | — |
| 1012.56.01020 Boehringer Ingelheim Investigational Site | Sepulveda | California | — | — |
| 1012.56.01045 Boehringer Ingelheim Investigational Site | Torrence | California | — | — |
| 1012.56.01040 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1012.56.01050 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 1012.56.01018 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1012.56.01062 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1012.56.01036 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 1012.56.01025 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1012.56.01088 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 1012.56.01007 Boehringer Ingelheim Investigational Site | Bay Pines | Florida | — | — |
| 1012.56.01058 Boehringer Ingelheim Investigational Site | Brandon | Florida | — | — |
| 1012.56.01010 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1012.56.01065 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1012.56.01024 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1012.56.01001 Boehringer Ingelheim Investigational Site | Melbourne | Florida | — | — |
| 1012.56.01023 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 1012.56.01052 Boehringer Ingelheim Investigational Site | Pensecola | Florida | — | — |
| 1012.56.01048 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1012.56.01093 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1012.56.01077 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1012.56.01083 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1012.56.01008 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1012.56.01019 Boehringer Ingelheim Investigational Site | Olathe | Kansas | — | — |
| 1012.56.01056 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 1012.56.01066 Boehringer Ingelheim Investigational Site | Bowling Green | Kentucky | — | — |
| 1012.56.01090 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 1012.56.01054 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1012.56.01072 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1012.56.01070 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1012.56.01035 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1012.56.01079 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1012.56.01044 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1012.56.01076 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1012.56.01082 Boehringer Ingelheim Investigational Site | Henderson | Nevada | — | — |
| 1012.56.01049 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 1012.56.01080 Boehringer Ingelheim Investigational Site | Brick | New Jersey | — | — |
| 1012.56.01027 Boehringer Ingelheim Investigational Site | Cherry Hill | New Jersey | — | — |
| 1012.56.01028 Boehringer Ingelheim Investigational Site | Summit | New Jersey | — | — |
| 1012.56.01069 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1012.56.01022 Boehringer Ingelheim Investigational Site | Larchmont | New York | — | — |
| 1012.56.01015 Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| 1012.56.01068 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1012.56.01078 Boehringer Ingelheim Investigational Site | Asheville | North Carolina | — | — |
| 1012.56.01017 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1012.56.01042 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1012.56.01034 Boehringer Ingelheim Investigational Site | Sylvania | Ohio | — | — |
| 1012.56.01031 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1012.56.01038 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1012.56.01016 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1012.56.01067 Boehringer Ingelheim Investigational Site | Hershey | Pennsylvania | — | — |
| 1012.56.01003 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1012.56.01060 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1012.56.01004 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1012.56.01087 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1012.56.01057 Boehringer Ingelheim Investigational Site | Johnston | Rhode Island | — | — |
| 1012.56.01026 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1012.56.01037 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1012.56.01081 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1012.56.01085 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1012.56.01084 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1012.56.01011 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1012.56.01073 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 1012.56.01075 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 1012.56.01047 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1012.56.01014 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1012.56.01032 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1012.56.01002 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1012.56.01053 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1012.56.01009 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1012.56.01013 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1012.56.01059 Boehringer Ingelheim Investigational Site | Roanoke | Virginia | — | — |
| 1012.56.01055 Boehringer Ingelheim Investigational Site | Salem | Virginia | — | — |
| 1012.56.01063 Boehringer Ingelheim Investigational Site | Bellington | Washington | — | — |
| 1012.56.01005 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1012.56.01064 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1012.56.01030 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 1012.56.01074 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
Recently updated Pulmonary Disease, Chronic Obstructive trials
Other public records listing Pulmonary Disease, Chronic Obstructive. Sorted by last update posted; newest first. Not a recommendation.
- NCT07759245: A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Not yet recruiting
- NCT07177339: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Recruiting
- NCT07714252: Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD Not yet recruiting
- NCT05718102: Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD Active, not recruiting
- NCT04669743: Innate Immunity in Ozone-induced Airway Inflammation in COPD Active, not recruiting
- NCT06961214: Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00400153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00400153 live on ClinicalTrials.gov.